Date:8/18/2010

ions will turn out to be correct, and investors are cautioned that actual results may differ materially from those described in the forward-looking statements in this press release. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's heavy dependence on the success of Xianling Gubao; the Company's ability to market Xianling Gubao to hospitals and to retail pharmacies; the retail prices of its principal products' being subject to price control by the government authorities in China; the inclusion of the Company's products in national and provincial medical catalogs of the National Medical Insurance Program in China; the Company's ability to obtain approval from the State Food and Drug Administration in China to convert a provisional national production standard of the Company's principal products to a national final production standard; the Company's ability to continue having the exclusive production rights for its products; the Company's ability to further improve its barrenwort extraction efficiency; the presence of certain side effects in the Company's current products and the Company's ability to identify side effects associated with its current or future products prior to their marketing and sale; the Company's ability to obtain manufacturing or marketing approval for its future products; the Company's dependence on a limited number of distributors for a significant portion of its net revenues; the Company's exposure to the risk of product liability claims and its limited insurance coverage; the Company's ability to manage the expansion of its operations and its future research and development projects successfully; the Company's ability to protect its intellectual property rights and defend infringement or misappropriation claims by third parties; intense competition in the pharmaceutical market in China; the supply of quality medici
'/>"/>

SOURCE Tongjitang Chinese Medicines Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine technology :

1. Tongjitang Files 2009 Annual Report on Form 20-F
2. Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results
3. Tongjitang Chinese Medicines Acquires Guiyang Liquor Factory
4. China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
5. China BCT Signs Exclusive Distribution Contract With Liujiang County Chinese Medicine Hospital
6. Biosites Triage Products Seized by Beijing Customs; Chinese Market Facing Shortage
7. China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology
8. Chinese Distribution Contract Extended for an Additional 4 Years
9. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
10. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
11. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government